{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:08:23Z","timestamp":1759342103872,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.annpat.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T15:58:32Z","timestamp":1383235112000},"page":"375-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effets secondaires carcinog\u00e8nes et r\u00e9sistances aux th\u00e9rapies cibl\u00e9es anti-BRAF"],"prefix":"10.1016","volume":"33","author":[{"given":"Mathieu","family":"Capovilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2013.09.003_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0010","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1755-148X.2010.00779.x","article-title":"Oncogenic RAF: a brief history of time","volume":"23","author":"Solit","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0020","doi-asserted-by":"crossref","first-page":"ra90","DOI":"10.1126\/scisignal.2001212","article-title":"The mammalian MAPK\/ERK pathway exhibits properties of a negative feedback amplifier","volume":"3","author":"Sturm","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.annpat.2013.09.003_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1078-0432.CCR-12-0383","article-title":"Molecular pathways: mitogen activated protein kinase (MAPK) pathway mutations and drug resistance","volume":"19","author":"Pritchard","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0030","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0035","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.annpat.2013.09.003_bib0045","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic BRAF induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0050","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"Lin","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2013.09.003_bib0055","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","article-title":"Increased cyclin D1\u00a0expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annpat.2013.09.003_bib0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.annpat.2013.09.003_bib0065","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From genes to drugs: targeted strategies for melanoma","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annpat.2013.09.003_bib0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0075","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jnci\/djp309","article-title":"Polyclonality of BRAF mutations in acquired melanocytic nevi","volume":"101","author":"Lin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.annpat.2013.09.003_bib0080","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.annpat.2013.09.003_bib0085","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0100","first-page":"24","article-title":"Traitement du m\u00e9lanome par les inhibiteurs de BRAF","volume":"1","author":"Robert","year":"2012","journal-title":"Correspondances en onco-th\u00e9ranostic"},{"key":"10.1016\/j.annpat.2013.09.003_bib0105","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-07-4123","article-title":"A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel","volume":"14","author":"Flaherty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0110","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0125","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0130","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3\u00a0randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annpat.2013.09.003_bib0140","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600\u00a0mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJMe1111636","article-title":"RAF around the edges\u00a0\u2013\u00a0the paradox of BRAF inhibitors","volume":"366","author":"Weeraratna","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0155","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0160","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0170","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0420","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2133.2009.09480.x","article-title":"Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers","volume":"162","author":"Zaravinos","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0190","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archdermatol.2012.2649","article-title":"Dynamic changes in nevi of a patient with melanoma treated with Vemurafenib: importance of sequential dermoscopy","volume":"148","author":"Haenssle","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0195","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0200","first-page":"1450","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0205","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0210","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccr.2012.01.017","article-title":"The RAF inhibitor paradox revisited","volume":"21","author":"Cox","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0220","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0225","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2013.09.003_bib0230","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1\u00a0expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMe1005370","article-title":"Melanoma\u2013an unlikely poster child for personalized cancer therapy","volume":"363","author":"Smalley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos Pl","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0245","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0250","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/13543784.2011.546218","article-title":"Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma","volume":"20","author":"Vito","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.annpat.2013.09.003_bib0260","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant BRAF-inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annpat.2013.09.003_bib0265","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","article-title":"Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma","volume":"25","author":"Sensi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2013.09.003_bib0270","doi-asserted-by":"crossref","first-page":"41797","DOI":"10.1074\/jbc.M112.390906","article-title":"SHOC2\u00a0and CRAF mediate ERK1\/2\u00a0reactivation in mutant NRAS-mediated resistance to RAF inhibitor","volume":"287","author":"Kaplan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.annpat.2013.09.003_bib0275","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harbouring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.annpat.2013.09.003_bib0280","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.annpat.2013.09.003_bib0285","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0290","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0295","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1\u00a0mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.annpat.2013.09.003_bib0300","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0305","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","article-title":"Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma","volume":"287","author":"Yadav","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.annpat.2013.09.003_bib0310","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0315","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1158\/1078-0432.CCR-10-0174","article-title":"Targeting BRAF in advanced melanoma: a first step towards manageable disease","volume":"17","author":"Vultur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0320","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2010.408","article-title":"Hyperactivation of MEK-ERK1\/2\u00a0signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor PLX4032, in mutant N-Ras melanoma cell lines","volume":"30","author":"Kaplan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2013.09.003_bib0325","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.annpat.2013.09.003_bib0335","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature09882","article-title":"DHODH modulates transcriptional elongation in the neural crest and melanoma","volume":"471","author":"White","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0340","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/erm.2012.11","article-title":"MEK and RAF inhibitors for BRAF-mutated cancers","volume":"14","author":"Belden","year":"2012","journal-title":"Exp Rev Mol Med"},{"key":"10.1016\/j.annpat.2013.09.003_bib0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0350","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0425","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2013.32","article-title":"Stat3-targeted-therapies overcome the acquired resistance to vemurafenib in melanomas","volume":"133","author":"Liu","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0360","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0365","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0370","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0375","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0380","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0385","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4161\/onci.19865","article-title":"Combined targeted therapy and immunotherapy in the treatment of advanced melanoma","volume":"1","author":"Wilmott","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annpat.2013.09.003_bib0390","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1517\/14656566.2012.737780","article-title":"Vemurafenib for the treatment of melanoma","volume":"13","author":"Jordan","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.annpat.2013.09.003_bib0395","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annpat.2013.09.003_bib0400","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","article-title":"Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor","volume":"22","author":"Seghers","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annpat.2013.09.003_bib0405","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S1470-2045(12)70539-9","article-title":"Which drug, and when, for patients with BRAF-mutant melanoma?","volume":"14","author":"Jang","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annpat.2013.09.003_bib0410","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.2013.29","article-title":"BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma","volume":"108","author":"Wilmott","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2013.09.003_bib0415","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.2010.34.0497","article-title":"Is it good or bad to find a BRAF mutation?","volume":"29","author":"Flaherty","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024264981300151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024264981300151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:31:42Z","timestamp":1759332702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024264981300151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S024264981300151X"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2013.09.003","relation":{},"ISSN":["0242-6498"],"issn-type":[{"type":"print","value":"0242-6498"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets secondaires carcinog\u00e8nes et r\u00e9sistances aux th\u00e9rapies cibl\u00e9es anti-BRAF","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}